A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)
A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Finasteride Spray (CU-40102) in Chinese Adult Male Patients With Androgenetic Alopecia (AGA)
In the register
The register attaches this trial to Topical finasteride (Almirall), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 3
- Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
- Participants (registry)
- 270
- Start
- December 2021
- Primary completion
- March 2023
- Study completion
- May 2023
- Last registry update
- August 2023
- Countries
- China
Conditions studied: AGA
Interventions: CU-40102 Spray
Other trials of Topical finasteride
Various Procedural Treatment Options for Androgenetic Alopecia
Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia
Photosensitization Study in Androgenetic Alopecia
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.